Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Luye Pharma Group ( (HK:2186) ) has provided an announcement.
Luye Pharma Group has updated the terms of reference for its Nomination Committee, originally adopted in 2014 and amended most recently on 31 December 2025, to refine governance around director appointments and Board composition. The revised framework formalizes the committee’s purpose of identifying, screening and recommending Board candidates, setting nomination guidelines, requiring a majority of independent non-executive directors on the committee, mandating at least one member of a different gender, and detailing procedures for meetings, access to management, resource support and annual self-evaluation, reinforcing the company’s corporate governance practices and oversight of Board succession.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company listed in Hong Kong, focused on the research, development, manufacturing and commercialization of medicines, with operations conducted through its subsidiaries as a group.
Average Trading Volume: 22,731,099
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$10.92B
Find detailed analytics on 2186 stock on TipRanks’ Stock Analysis page.